Lilly Reports Strong Q4, $7B Kelonia Deal, Foundayo Sales Up; Stock Falls
Summary
Eli Lilly reported robust Q4 revenue of $19.29 billion, a 42.6% year-over-year increase, significantly beating estimates, and raised its full-year revenue guidance. Concurrently, the company announced a major strategic acquisition of Kelonia Therapeutics for up to $7.0 billion, including $3.25 billion upfront, to enhance its CAR-T gene therapy capabilities. Additionally, specific prescription data for its new oral obesity drug, Foundayo, showed an increase from 1,390 in week one to 3,707 in week two. Despite these seemingly positive developments, Eli Lilly's stock experienced a notable decline of 8.5% after the earnings report and a 4% drop following the Foundayo sales data, indicating that market expectations were even higher or that other factors are weighing on investor sentiment. Traders will be closely watching the integration of Kelonia and the continued sales trajectory of Foundayo to understand the market's current valuation of LLY.
At the time of this announcement, LLY was trading at $883.66 on NYSE in the Life Sciences sector, with a market capitalization of approximately $835.2B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.